NCT00622830已完成1 期
Phase I Study of SB-480848 (Darapladib) -A Double Blind, Randomised, Placebo-controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-480848 in Healthy Japanese Male Subjects-
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Primary Pharmacokinetic parameters of repeat oral doses of darapladib
研究概览
简要总结
This study is being conducted to provide safety, tolerability, PK and PD data in repeat dosing that will allow further studies with darapladib in Japanese patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy Japanese adult males between 20 and 64 yeas of age, inclusive.
- •Healthy subjects are defined as individuals who are free from clinically significant disease as determined by their medical history, physical examination, clinical laboratory examinations, vital sign, 12-lead ECG, immunology tests and urinary drug screen test.
- •Bodyweight >50 kg and body mass index (BMI) between 18.5 and 25.0 at screening.
- •Subjects must be capable of providing written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •Baseline QTc interval <450 msec.
- •Non-smoker or ex-smoker having ceased smoking for at least 6 months.
- •Clinical laboratory examination (AST, ALT, ALP and GGT) at screening are within the normal range.
- •The subject is able to attend all visits and complete the study.
排除标准
- •Any clinically relevant abnormality identified on the screening physical examination, vital sign measurement, 12-lead ECG recording and/or clinical laboratory examination that is deemed by the principal investigator and/or medical monitor to make the subject ineligible for inclusion because of a safety concern.
- •History of regular alcohol consumption exceeding, on average, 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 350 mL of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits) within 6 months of screening.
- •Positive for urine drug at screening.
- •Positive for syphilis, HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody or HTLV-1 antibody at screening.
- •Use of prescription or no-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- •Consumption of grapefruit juice or food within 7 days prior to the first dose of study medication.
- •A history of cholecystectomy or biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology.
- •Donation of blood in excess of 400mL within 4 months or 200mL within 1 months prior to at screening.
- •History of drug abuse, or current conditions of drug abuse or alcoholism.
- •Participation in a clinical study or post-marketing study with an investigational or a non-investigational product or device within 4 months of preceding the first dose of study medication.
- •Participation in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational product or device.
- •History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses.
- •The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia.
结局指标
主要结局
Primary Pharmacokinetic parameters of repeat oral doses of darapladib
Safety/tolerability of repeat oral doses of darapladib
次要结局
- -Secondary PK parameters
- Plasma Lp-PLA2 activity, expressed in terms of percent inhibition relative to baseline
- -inhibition of Lp-PLA2 activity
- -description of plasma concentration-Lp-PLA2 activity inhibition relationship after repeat oral doses of darapladib. all measured same timepoints as primary
- -PK parameters of SB553253
- Tmax, and t1/2 of SB-480848 and AUC, Cmax, t1/2 and Tmax of the pharmacologically active metabolite SB-553253 (as data permit)
- Estimation of PK/PD parameters and their associated variability, appropriate to the final models
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia PatientHemophiliaNCT05493631GC Biopharma Corp15
已完成
1 期
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsPostbariatric HypoglycemiaNCT06036784MBX Biosciences69
已完成
1 期
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema ParticipantsHereditary Angioedema (HAE)NCT02093923Shire38
终止
1 期
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung CancerNSCLCNCT05492045InventisBio Co., Ltd22
Unknown
1 期
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy AloneHepatitis CNCT01025297Cytheris SA18